Hello, everyone, and how are you this fine morning? We are doing just keen, despite the gathering snow that is collecting on the Pharmalot campus. In fact, the scene is actually quite pleasant, although we are foraging around for the appropriate boots and gloves and shovels that will be needed later. Meanwhile, we are firing up the trusty coffee kettle because cups of stimulation will be very much needed. Feel free to join us. And now, here are some items of interest to distract you. Hope your day is smashing and, as always, keep us in mind when you get a hot news flash …

A Johnson & Johnson (JNJ) treatment-resistant depression drug called Esketamine faces an uncertain fate at a Food and Drug Administration advisory committee meeting on Tuesday, as panel members ponder a mixed bag of clinical trial success, Benzinga explains. Treatment-resistant depression refers to patients with major depressive disorder who have not responded to at least two different treatments with antidepressants in a moderate-to-severe depressive episode. FDA reviewers raised safety concerns, but did not appear overly concerned about abuse potential.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • While our scribe flags ‘executives,’ the donation stats related to Senator Booker are for ‘contributions from the pharmaceutical industry and its employees.’ One wonders how much of the amount were from ‘small dollar’ donations by employees vs big dollar from firms or ‘the corporate brass.’

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy